Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHJ002 in Dry Eye Disease
NCT05486728Phase 2Completed
- Sponsor
- Dreamhawk Vision Biotech, Inc.
- Start
- Feb 2023
- Primary completion
- Dec 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
A Phase 2 trial of SHJ002 in dry eye disease (DED), sponsored by Dreamhawk Vision Biotech, Inc.. Started Feb 2023; status: completed.
02
Drugs
SHJ002
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05486728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05486728.